Since cyst(e)inase treatment can induce intracellular cystine degradation consequent promotion of cancer cell ferroptosis [88], the combined cyst(e)inase with PD-L1 antibody effectively enhances tumor immunotherapy [86], suggesting that combined ferroptosis inducers with immune checkpoint inhibitors could effectively enhance cancer immunotherapy. Here, CD274 is linked to cancer.